Calithera Biosciences (CALA) Given Consensus Recommendation of “Hold” by Brokerages

Share on StockTwits

Shares of Calithera Biosciences (NASDAQ:CALA) have received an average recommendation of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $17.67.

A number of research firms have recently issued reports on CALA. Zacks Investment Research lowered Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 13th. ValuEngine lowered Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, February 3rd. Citigroup upgraded Calithera Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $6.95 to $14.00 in a report on Friday, February 16th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Calithera Biosciences in a report on Friday, April 6th.

Shares of CALA traded down $0.15 during mid-day trading on Thursday, reaching $5.15. The company’s stock had a trading volume of 440,948 shares, compared to its average volume of 509,436. The firm has a market capitalization of $189.98 million, a P/E ratio of -6.13 and a beta of 2.62. Calithera Biosciences has a 1 year low of $4.85 and a 1 year high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). The business had revenue of $5.19 million during the quarter, compared to analysts’ expectations of $7.28 million. Calithera Biosciences had a negative net margin of 131.51% and a negative return on equity of 22.92%. equities analysts expect that Calithera Biosciences will post -1.4 earnings per share for the current year.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Calithera Biosciences by 11.9% during the first quarter. BlackRock Inc. now owns 3,229,031 shares of the biotechnology company’s stock worth $20,344,000 after acquiring an additional 342,756 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Calithera Biosciences by 198.6% during the fourth quarter. Millennium Management LLC now owns 1,439,573 shares of the biotechnology company’s stock worth $12,020,000 after acquiring an additional 957,437 shares in the last quarter. Federated Investors Inc. PA purchased a new stake in shares of Calithera Biosciences during the first quarter worth $8,960,000. American Century Companies Inc. raised its holdings in shares of Calithera Biosciences by 32.1% during the first quarter. American Century Companies Inc. now owns 796,726 shares of the biotechnology company’s stock worth $5,019,000 after acquiring an additional 193,607 shares in the last quarter. Finally, Ascend Capital LLC raised its holdings in shares of Calithera Biosciences by 5.4% during the fourth quarter. Ascend Capital LLC now owns 693,801 shares of the biotechnology company’s stock worth $5,792,000 after acquiring an additional 35,606 shares in the last quarter. Institutional investors and hedge funds own 64.91% of the company’s stock.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Prologis Inc  Expected to Announce Quarterly Sales of $560.63 Million
Prologis Inc Expected to Announce Quarterly Sales of $560.63 Million
Zacks: Brokerages Expect Kadant Inc.  Will Announce Earnings of $0.99 Per Share
Zacks: Brokerages Expect Kadant Inc. Will Announce Earnings of $0.99 Per Share
Independence  Receiving Somewhat Favorable Press Coverage, Analysis Finds
Independence Receiving Somewhat Favorable Press Coverage, Analysis Finds
David Edward Johnson Buys 50,000 Shares of Diversified Gas & Oil PLC  Stock
David Edward Johnson Buys 50,000 Shares of Diversified Gas & Oil PLC Stock
Greenlight Capital Re  Earning Somewhat Favorable Press Coverage, Analysis Shows
Greenlight Capital Re Earning Somewhat Favorable Press Coverage, Analysis Shows
Blackrock Muni Intermediate Drtn Fnd  Earns Coverage Optimism Score of 0.08
Blackrock Muni Intermediate Drtn Fnd Earns Coverage Optimism Score of 0.08


© 2006-2018 Ticker Report. Google+.